Pfizer beats earnings expectations with adjusted EPS of $0.87 and revenue of $16.65 billion, leading to a 12.6% stock jump in pre-market trading. Despite a 20.84% net income drop, non-COVID revenue grows by 4%, driven by key franchises like Eliquis and Vyndaqel.

Management reaffirms full-year revenue guidance but raises EPS outlook. Strategic actions, like the proposed Metsepa acquisition, signal Pfizer’s active portfolio reshaping. The company’s 36% EPS beat marks the sixth consecutive quarterly outperformance, reflecting strong execution and consistent growth.

Pfizer trades at a low forward P/E of 8.67, offering a 6.9% dividend yield. Institutional ownership is at 65.47%, with a beta of 0.465, indicating a defensive holding. Analyst consensus leans towards Hold, with an average price target of $28.75, suggesting a 15.60% potential upside from current levels.

Read more at Yahoo Finance: Pfizer’s Q3 Earnings Beat on Top and Bottom Lines